1 / 1

With two approved drugs and close to 300 clinical / preclinical product candidates, By Roots Analysis

With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.<br> <br>To order this 370 page report, which features 90 figures and 110 tables, please visit this https://www.rootsanalysis.com/reports/286/request-sample.html<br>

kevin987
Download Presentation

With two approved drugs and close to 300 clinical / preclinical product candidates, By Roots Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    More Related